Filamentous Fungi Cofactor Engineering Patents: Leaders & Gaps 2026
Filamentous Fungi Cofactor Engineering Patents: Who Holds the Redox Claims
63.4% concentration. The top 5 assignees hold 59 of 93 records in scope — a small group controls most of the documented redox and cofactor-recycling claims. Filings peaked at 7 in 2018 and have since settled into a lower, flatter band; the 2021-to-2024 window is flat at 4 filings per year (0% change), and 2025-2026 figures will rise as later publications land.
- 1DSM IP ASSETS BV21
- 2CODEXIS INC13
- 3PHARMACIA CORP11
- 4NEDERLANDSE ORG VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO8
- 5NAT TAIWAN UNIV6
See the full filamentous fungi cofactor engineering analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on filamentous fungi cofactor engineering patents
Who holds the most patents in filamentous fungi cofactor engineering?
One assignee leads with 21 of the 93 records in scope, a clear margin over fifth place at 6 records and tenth place at 3. The top 5 assignees together hold 59 records, or 63.4% of all records in scope, and the top 10 hold 82.8%. This means the field is concentrated at the top with a long tail of smaller filers behind the leaders rather than being evenly spread across many companies.
Is patent filing in this field growing or shrinking?
Filing activity peaked in 2018 at 7 records and has since settled lower, with the 2021-to-2024 window flat at 4 filings per year — 0% growth across that span. Because publication lags filing by roughly 18 months, the 2025-2026 figures in any dataset will understate real activity and should not yet be read as a decline. The honest read is a plateaued field, not a growing or a shrinking one.
What IPC classes matter most for cofactor engineering in fungal hosts?
C12N, covering microorganisms and genetic engineering, appears in 91.4% of the 93 records in scope, making it the dominant classification. C12P, fermentation and enzymatic synthesis, follows at 55.9%, and C12Q, enzyme and DNA measurement methods, at 31.2%. Records can carry more than one class, so these figures overlap rather than sum to 100%, but together they show the field is anchored in host engineering and bioprocess rather than in downstream therapeutic use.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Filamentous Fungi Cofactor Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.